表紙
市場調查報告書
商品編碼
1063800

口服蛋白/peptone市場(第 4 版):按目標疾病適應症,按分子類型

Oral Proteins and Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide),

出版日期: | 出版商: Roots Analysis | 英文 421 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

洞察示例

口服蛋白和多peptone領域有很大的機會。鑑於口服蛋白質和多peptone的健康臨床管道,預計該領域將繼續快速增長。

基於蛋白質/peptone的療法由於其廣泛的用途和針對特定目標的特性而徹底改變了製藥行業。口服蛋白質/peptone治療市場預計將在未來十年顯著增長。

本報告探討了口服蛋白質和多peptone市場,並概述了市場,以及公司的競爭格局、關鍵治療領域、藥物概況、臨床試驗和專利趨勢。

目錄

第一章前言

第2章執行摘要

第三章介紹

  • 章節概述
  • 生物製藥與小分子藥物的比較
  • 蛋白質介紹
  • peptone介紹
  • 蛋白質/peptone給藥途徑
  • 口服蛋白質/多peptone
  • 用於提高結構和生物利用度的方法
  • 結束語

第 4 章市場概述

  • 章節概述
  • 口服蛋白/多peptone療法:市場行情
  • 口服蛋白/peptone療法:開發者情況

第五章企業競爭力分析

  • 章節概述
  • 主要先決條件和參數
  • 口服蛋白/peptone療法開發商:競爭力分析

第 6 章重要見解

第7章KOL分析

第8章主要治療領域

  • 章節概述
  • 代謝紊亂
    • 糖尿病
    • 肥胖
    • 非酒精性脂肪性肝炎 (NASH)
  • 消化和胃腸道疾病
    • 潰瘍性結腸炎
    • 克羅恩病
  • 傳染病
    • 艱難梭菌感染 (CDI)
  • 自身免疫性疾病
    • 乳糜瀉
  • 荷爾蒙失調
    • 肢端肥大症
  • 骨骼疾病
    • 骨質疏鬆症

第 9 章商業和晚期藥物概況

第10章案例研究:Minilin(R),Sandimne(R),Solpra(R)

第11章口服蛋白/多peptone開發技術:市場情況

  • 章節概述
  • 口服蛋白/多peptone開發技術:市場形勢
  • 口服蛋白/多peptone開發技術:開發者情況

第12章產品競爭力分析

  • 章節概述
  • 範圍及調查方法
  • 產品競爭力分析:關鍵技術

第十三章口服給藥技術平台

  • 章節概述
  • 口服給藥:技術平台列表
  • 技術簡介

第十四章融資與投資分析

  • 章節概述
  • 資金類型
  • 口服蛋白/多peptone:融資與投資分析
  • 結束語

第15章近期合作

  • 章節概述
  • 合作模式
  • 口服蛋白質/peptone:夥伴關係和合作

第16章出版物分析

第17章臨床試驗分析

  • 章節概述
  • 範圍及調查方法
  • 口服蛋白/多peptone療法:臨床試驗分析

第十八章專利分析

  • 章節概述
  • 範圍及調查方法
  • 口服蛋白/多peptone療法:專利分析
  • 口服蛋白/peptone療法:專利基準分析
  • 口服蛋白/多peptone療法:專利評價分析

第19章大規模藥物分析

  • 章節概述
  • 重要的先決條件和研究方法
  • 口服蛋白/多peptone療法:各大製藥公司的舉措

第 20 章市場預測和機會分析

  • 章節概述
  • 範圍和限制
  • 預測調查法
  • 2022-2032年全球口服蛋白/peptone治療市場
  • 口服蛋白/peptone市場:按產品分類的銷售預測

第 21 章案例研究:蛋白質/peptone生產

第22章關鍵商業化/生命週期管理策略

第23章SWOT分析

第24章結論

第 25 章執行洞察力

第26章附錄1:最新動態

第27章附錄2:聚合數據

第28章附錄3:公司名單

目錄

Title:
Oral Proteins and Peptides Market (4th Edition)
by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players, and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032.

Example Insights:

Overview:

The field of oral proteins / peptides has enormous opportunities. I believe the field will continue to grow at a rapid pace considering the healthy clinical pipeline of oral proteins / peptides. - Chief Executive Officer, US based small-sized developer.

Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides. Interestingly, in the last decade, three orally administered protein / peptide-based therapies have been approved, namely Mycapssa® (2020), Trulance® (2017) and Linzess® (2012) across different geographies. The rising popularity of this upcoming class of therapeutics has led to the reformulation / development of oral protein / peptide-based product candidates for the treatment of a myriad of disease indications across multiple therapeutic areas (including but not limited to metabolic disorders, gastrointestinal disorders, autoimmune disorders). It is worth mentioning that oral administration is a favorable route for delivery of drugs to pediatric and geriatric patients, primarily due to its non-invasive nature. In addition, the ease of administration associated with the oral delivery method has been demonstrated increase treatment adherence to as well as reduce the risk of non-compliance.

Protein / peptide-based therapeutics have revolutionized the pharmaceutical landscape, this can be attributed to the wide applications and target specific nature of such interventions. However, oral formulations of protein / peptide-based drugs have been associated with several drawbacks, including poor bioavailability and drug decomposition in the gastrointestinal tract. In order to mitigate the aforementioned challenges, players engaged in this domain have conducted extensive research for the development of novel biological targets, thereby, strengthening their research pipelines. In addition, this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of developers. It is also worth mentioning that, over the last few years, the market has witnessed an active participation of big pharma players and substantial partnership activity. Given the ongoing research and development initiatives and an encouraging response to the already marketed drugs, the oral protein / peptide therapies market is poised to witness significant growth over the coming decade.

Scope of the Report:

The 'Oral Proteins and Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players, and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032' report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, along with the future market potential. In addition, it provides an in-depth analysis, highlighting the market landscape of technology providers engaged in this domain. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of oral proteins / peptides, providing information on the developer, type of molecule (protein or peptide), phase of development (commercial, clinical, preclinical or discovery stage), target therapeutic area(s), biological target, mechanism of action, number of amino acids and affiliated technology platform. In addition, the chapter includes information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters.
  • A detailed competitiveness analysis of oral protein / peptide therapy developers based on several relevant parameters, such as supplier power (in terms of years of experience and employee count), pipeline strength and phase of development.
  • An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a four dimensional grid analysis, representing the distribution of oral proteins / peptides (on the basis of the type of molecule) across various target therapeutic areas and stages of development, [B] a logo landscape of companies involved in the development of oral protein / peptide-based drugs, distributed on the basis of phase of development of pipeline candidates and size of developer companies (small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the most active geographies, in terms of the presence of various industry players engaged in the development of oral proteins / peptides.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field.
  • An overview of the current market landscape of technology platforms available for the development of oral protein / peptide therapeutics, along with information on their developer, type of platform, compatible API types, target therapeutic area, dosage form and status of development of products. In addition, the chapter includes information on technology developer(s), highlighting their year of their establishment, company size and location of headquarters.
  • A 2X2 matrix, comparing product competitiveness and supplier power of the technology platforms that are presently being used for the development of oral proteins / peptides. The analysis takes into consideration several parameters, such as year of establishment, company size and development activity (number of drugs in both preclinical / clinical stages of development).
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
  • An analysis of the partnerships that have been established in the domain, over the last five years, covering licensing agreements, acquisitions, R&D agreements, product commercialization agreements, clinical trial agreements and other relevant deals.
  • A detailed review of more than 300 peer-reviewed, scientific articles related to research on oral protein / peptides, which have been published since 2017.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players (industry and non-industry) and regional distribution of trials.
  • An in-depth analysis of the patents related to oral protein / peptides, filed / granted since 2017, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • An analysis of big pharma players engaged in this domain, featuring a spider-web analysis based on several relevant parameters, such as number of pipeline candidates, partnership agreements and publications.
  • A detailed case study on protein / peptide contract manufacturing, featuring a list of over 140 CMOs that are currently offering contract manufacturing services for such products / product candidates.
  • An elaborate discussion on the various commercialization and lifecycle management strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall oral proteins / peptides market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the future size of the market based on various parameters, such as target consumer segments, likely adoption rates and expected pricing. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2032. In addition, we have provided the likely distribution of the market based on [A] target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), [B] type of molecule (protein and peptide), [C] technology platforms, [D] biological target (GC-C, insulin receptor, oxalate, others), [E] mechanism of action (receptor stimulation, substrate degradation and others) [F] key players, and [G] key geographical regions (North America, Europe, Asia-Pacific and RoW). In order to account for the uncertainties associated with the growth of the oral proteins / peptides market and to add robustness to our model, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (CEO, Constant Therapeutics).

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players involved in the development of oral protein / peptide therapeutics?
  • Which technologies are leveraged the most by oral protein / peptide therapy developers?
  • Who are the key opinion leaders in this domain?
  • Which geographies are the most active in conducting clinical trials focused on oral protein / peptide therapeutics?
  • Which companies have received the maximum funding for the development for oral protein / peptide therapeutics? Who are the most prominent investors?
  • Which partnership models are commonly adopted by industry stakeholders in the development of oral protein / peptide therapeutics?
  • Which organizations have filed the maximum number of patents in this field?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of oral protein / peptide therapeutics market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a comparison of the key characteristics of small molecules and large molecules / biologics. In addition, it includes a detailed discussion on proteins / peptides, highlighting their potential as therapeutic agents. Further, it features a discussion on the various routes of administration used for the delivery of drugs, with special focus on oral route. The chapter elaborates on the likely advantages and challenges associated with the oral route of administration. In addition, it includes a comprehensive discussion on the various approaches developed / under development for the effective oral delivery of proteins / peptides.

Chapter 4 includes information on over 125 programs for oral protein / peptide therapeutics that are either approved or being developed across different stages (commercial, clinical, preclinical or discovery stage) for the treatment of various indications. It features a comprehensive analysis of pipeline molecules, based on the type of molecule (protein or peptide), phase of development (commercial, clinical, preclinical or discovery stage), target therapeutic area(s), biological target, mechanism of action, number of amino acids and affiliated technology platform. In addition, the chapter includes information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters.

Chapter 5 provides a detailed competitiveness analysis of oral protein / peptide therapy developers based on several relevant parameters, such as supplier power (in terms of years of experience and employee count), pipeline strength and phase of development.

Chapter 6 presents the key insights derived from the study. It features an in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a four dimensional grid analysis, representing the distribution of oral proteins / peptides (on the basis of the type of molecule) across various target therapeutic areas and stages of development, [B] a logo landscape of companies involved in the development of oral protein / peptide-based drugs, distributed on the basis of phase of development of pipeline candidates and size of developer companies (small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the most active geographies, in terms of the presence of various industry players engaged in the development of oral proteins / peptides

Chapter 7 provides a detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.

Chapter 8 highlights the potential target indications (segregated by therapeutic areas) that are currently the prime focus of companies developing oral proteins / peptides. These include metabolic disorders, gastrointestinal disorders and autoimmune disorders. The chapter also provides details on disease epidemiology, available diagnostic tests, and currently available treatment options for each indication and their likely side effects.

Chapter 9 contains detailed profiles of drugs that are either marketed or are in late stage (phase II / III and above) of development. Each profile features an overview of the drug, history of development, mechanism of action, dosage information (if available), manufacturing information (if available), current status of development, clinical trial information, key clinical trial results, historical sales (if marketed) and information on the developer.

Chapter 10 provides a review of oral proteins / peptides belonging other drug classes, namely cyclic peptides and PERTs, which are either commercialized or still under development. The chapter features detailed profiles of three popular orally administrable, therapeutic proteins / peptides (Minirin®, Sandimmune® and Sollpura®), which were discovered before 2000. Each profile contains an overview of the drug, history of development, chemical structure and mechanism of action, dosage information (if marketed), clinical trial information (if the product is currently under development), patent portfolio (if available) and information on the other commercially available treatment options for the disease indications for which each drug is approved.

Chapter 11 provides an overview of the market landscape of technology platforms available for the development of oral protein/ peptide therapeutics, including an analysis based on parameters, such as type of platform (drug formulation, drug development), compatible API types (peptide, protein and others), target therapeutics area, dosage form and status of development of products. In addition, the chapter also includes an analysis on the companies developing these platforms, based on year of their establishment, company size, and location of headquarters.

Chapter 12 features a 2X2 matrix, comparing product competitiveness and supplier power of the oral drug delivery technology platforms that are presently being utilized for the generation of oral proteins / peptides. The analysis takes into consideration several parameters, such as year of establishment, company size and development activity (number of drugs in both preclinical / clinical stages of development).

Chapter 13 features detailed profiles of some of the key technologies that have been used to develop oral protein / peptide therapeutics. Each profile contains details on the technology, including mechanism of action, pipeline molecules developed using the technology, its advantages and the various partnerships that were established related to the technology.

Chapter 14 presents details on various investments received by companies that are engaged in the development of oral protein / peptide therapeutics and / or associated delivery technologies. It also includes detailed analysis of the funding instances, based on several parameters, such as number of instances, amount invested, type of funding, focus aera, area of application, target therapeutic area, most active players and geographical analysis.

Chapter 15 provides a detailed analysis of the recent collaborations established since 2017. It includes analysis based on relevant parameters, such as year of partnership, type of agreement, focus area, type of partner and regional distribution of partnerships.

Chapter 16 presents a detailed review of more than 300 peer-reviewed, scientific articles related to research on oral protein / peptides, which have been published since 2017, including analysis based on parameters, such as year of publication, key focus area, type of molecule, popular keywords, key journals (in terms of number of articles published in this domain and impact factor of the journal) and affiliations.

Chapter 17 presents a detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players (industry and non-industry) and regional distribution of trials.

Chapter 18 provides an in-depth analysis of the patents related to oral protein / peptides, filed / granted since 2017, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 19 presents an analysis of big pharma players engaged in this domain, featuring a spider-web analysis based on several relevant parameters, such as number of pipeline candidates, partnership agreements and publications.

Chapter 20 presents an insightful market forecast analysis, highlighting the likely growth of oral protein / peptide therapeutics market, till 2032. In order to provide a detailed future outlook, our projections have been segmented across [A] target disease indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), [B] type of molecule (protein and peptide), [C] technology platforms, [D] biological target (GC-C, insulin receptor, oxalate, others), [E] mechanism of action (receptor stimulation, substrate degradation and others) [F] key players, and [G] key geographical regions (North America, Europe, Asia-Pacific and RoW).

Chapter 21 features a case study on the role of CMOs in the field of oral proteins / peptides. It provides details on the various factors that need to be considered while selecting the right CMO partner for the pharmaceutical companies. In addition, it includes a list of over 140 contract manufacturers that claim to have the necessary capabilities for protein / peptide manufacturing.

Chapter 22 provides an elaborate discussion on the various commercialization and lifecycle management strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing stage.

Chapter 23 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the oral proteins / peptides market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall oral proteins / peptides market.

Chapter 24 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the oral protein / peptide therapeutics market.

Chapter 25 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (CEO, Constant Therapeutics).

Chapter 26 is an appendix, which provides tabulated information on the historical developments.

Chapter 27 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 28 is an appendix, which contains a list of companies and organizations.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Comparison of Biologics and Small Molecules
  • 3.3. Introduction to Proteins
    • 3.3.1. Protein Structure
    • 3.3.2. Classification of Proteins
  • 3.4. Introduction to Peptides
    • 3.4.1. Peptide Structure
    • 3.4.2. Classification of Peptides
      • 3.4.2.1. Synthetic Peptides
      • 3.4.2.2. Recombinant Peptides
  • 3.5. Routes of Administration for Proteins / Peptides
    • 3.5.1. Parenteral Administration
      • 3.5.1.1. Intramuscular Route
      • 3.5.1.2. Intravenous Route
      • 3.5.1.3. Subcutaneous Route
    • 3.5.2. Non-Parenteral Administration
      • 3.5.2.1. Buccal / Sublingual Route
      • 3.5.2.2. Intranasal Route
      • 3.5.2.3. Oral Route
      • 3.5.2.4. Ocular Route
      • 3.5.2.5. Pulmonary Route / Inhalation
      • 3.5.2.6. Rectal Route
      • 3.5.2.7. Transdermal Route
    • 3.5.3. Comparison of Different Routes of Drug Administration
  • 3.6. Oral Delivery of Proteins / Peptides
    • 3.6.1. Key Advantages of Oral Administration
    • 3.6.2. Key Challenges Associated with Oral Administration
  • 3.7. Approaches Used for Structural and Bioavailability Enhancement
    • 3.7.1. Absorption Enhancers
    • 3.7.2. Chemical Modification
      • 3.7.2.1 Pro Drug Approach
    • 3.7.3. Enzyme Inhibitors
    • 3.7.4. Muco-Adhesive Polymeric Systems
    • 3.7.5. Nanoparticular Delivery Systems
      • 3.7.5.1. Liposomes
      • 3.7.5.2. Nanoparticles / Microparticles
    • 3.7.6. PEGylation
  • 3.8. Concluding Remarks

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Oral Proteins / Peptide Therapeutics: Market Landscape
    • 4.2.1. Analysis by Type of Molecule
    • 4.2.2. Analysis by Phase of Development
    • 4.2.3. Analysis by Target Therapeutic Area
    • 4.2.4. Analysis by Biological Target
    • 4.2.5. Analysis by Mechanism of Action
    • 4.2.6. Analysis by Phase of Development and Mechanism of Action
    • 4.2.7. Analysis by Number of Amino Acids
    • 4.2.8. Key Drug Development Platforms: Analysis by Number of Products
  • 4.3. Oral Proteins / Peptide Therapeutics: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Company Size and Location of Headquarters
    • 4.3.5. Most Active Players: Analysis by Number of Pipeline Candidates

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Key Assumptions and Parameters
  • 5.3. Oral Protein / Peptide Therapy Developers: Competitiveness Analysis

6. KEY INSIGHTS

  • 6.1. Chapter Overview
  • 6.2. Oral Proteins / Peptides Pipeline: Grid Analysis
  • 6.3. Oral Proteins / Peptides Pipeline: Developer Landscape
  • 6.4. Oral Proteins / Peptides Pipeline: Regional Landscape (Industry Players)

7. KOL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Oral Protein / Peptide Therapeutics: List of Key Opinion Leaders
    • 7.2.1. Analysis by Type of Current Organization
    • 7.2.2. Analysis by Geography
      • 7.2.2.1. Analysis by Region (Continent-wise)
      • 7.2.2.2. Analysis by Region (Country-wise)
    • 7.2.3. Analysis by Number of Investigators and Current Organization
    • 7.2.4. Analysis by Qualification of KOL
    • 7.2.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
    • 7.2.6. Comparison of Roots Analysis Score v/s Third Party Score
    • 7.2.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
    • 7.2.8. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength

8. KEY THERAPEUTIC AREAS

  • 8.1. Chapter Overview
  • 8.2. Metabolic Disorders
    • 8.2.1. Diabetes
      • 8.2.1.1. Disease Description
      • 8.2.1.2. Associated Health Risks / Complications
      • 8.2.1.3. Epidemiology
      • 8.2.1.4. Disease Diagnosis
      • 8.2.1.5. Current Treatment Options
        • 8.2.1.5.1. Insulin Therapies
        • 8.2.1.5.2. Non-Insulin Therapies
      • 8.2.1.6. Side Effects of Current Treatment Options
      • 8.2.1.7. Oral Proteins / Peptides for Diabetes
    • 8.2.2. Obesity
      • 8.2.2.1. Disease Description
      • 8.2.2.2. Epidemiology
      • 8.2.2.3. Current Treatment Options
      • 8.2.2.4. Side Effects of Current Treatment Options
      • 8.2.2.5. Oral Proteins / Peptides for Obesity
    • 8.2.3. Non-alcoholic Steatohepatitis (NASH)
      • 8.2.3.1. Disease Description
      • 8.2.3.2. Epidemiology
      • 8.2.3.3. Current Treatment Options
      • 8.2.3.4. Oral Proteins / Peptides for NASH
  • 8.3. Digestive and Gastrointestinal Disorders
    • 8.3.1. Ulcerative Colitis
      • 8.3.1.1. Disease Description
      • 8.3.1.2. Epidemiology
      • 8.3.1.3. Current Treatment Options
      • 8.3.1.4. Side Effects of Current Treatment Options
      • 8.3.1.5. Oral Proteins / Peptides for Ulcerative Colitis
    • 8.3.2. Crohn's Disease
      • 8.3.2.1. Disease Description
      • 8.3.2.2. Epidemiology
      • 8.3.2.3. Current Treatment Options
      • 8.3.2.4. Side Effects of Current Treatment Options
      • 8.3.2.5. Oral Proteins / Peptides for Crohn's Disease
  • 8.4. Infectious Diseases
    • 8.4.1. C. difficile Infections (CDIs)
      • 8.4.1.1. Disease Description
      • 8.4.1.2. Epidemiology
      • 8.4.1.3. Disease Diagnosis
      • 8.4.1.4. Current Treatment Options
      • 8.4.1.5. Side Effects of Current Treatment Options
      • 8.4.1.6. Oral Proteins / Peptides for CDIs
  • 8.5. Autoimmune Disorders
    • 8.5.1. Celiac Disease
      • 8.5.1.1. Disease Description
      • 8.5.1.2. Epidemiology
      • 8.5.1.3. Disease Diagnosis
      • 8.5.1.4. Current Treatment Options
      • 8.5.1.5. Oral Proteins / Peptides for Celiac Disease
  • 8.6. Hormonal Disorders
    • 8.6.1. Acromegaly
      • 8.6.1.1. Disease Description
      • 8.6.1.2. Epidemiology
      • 8.6.1.3. Disease Diagnosis
      • 8.6.1.4. Current Treatment Options
      • 8.6.1.5. Side Effects of Current Treatment Options
      • 8.6.1.6. Oral Proteins / Peptides for Acromegaly
  • 8.7. Bone Disorders
    • 8.7.1. Osteoporosis
      • 8.7.1.1. Disease Description
      • 8.7.1.2. Epidemiology
      • 8.7.1.3. Disease Diagnosis
      • 8.7.1.4. Current Treatment Options
      • 8.7.1.5. Side Effects of Current Treatment Options
      • 8.7.1.6. Oral Proteins / Peptides for Osteoporosis

9. MARKETED AND LATE-STAGE DRUG PROFILES

  • 9.1. Chapter Overview
  • 9.2. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
    • 9.2.1. Drug Overview
    • 9.2.2. History of Development
    • 9.2.3. Mechanism of Action
    • 9.2.4. Dosage Form, Treatment Regimen and Price
    • 9.2.5. Manufacturing Information
    • 9.2.6. Current Status of Development
    • 9.2.7. Clinical Studies
    • 9.2.8. Key Clinical Trial Results
    • 9.2.9. Historical Sales
    • 9.2.10. Developer Overview
  • 9.3. Trulance® / Plecanatide (Synergy Pharmaceuticals)
    • 9.3.1. Drug Overview
    • 9.3.2. History of Development
    • 9.3.3. Mechanism of Action
    • 9.3.4. Dosage Form, Treatment Regimen and Price
    • 9.3.5. Manufacturing Information
    • 9.3.6. Current Status of Development
    • 9.3.7. Clinical Studies
    • 9.3.8. Key Clinical Trial Results
    • 9.3.9. Historical Sales
    • 9.3.10. Developer Overview
  • 9.4. TBRIA™ / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
    • 9.4.1. Drug Overview
    • 9.4.2. History of Development
    • 9.4.3. Mechanism of Action
    • 9.4.4. Manufacturing Information
    • 9.4.5. Current Status of Development
    • 9.4.6. Clinical Studies
    • 9.4.7. Key Clinical Trial Results
    • 9.4.8. Developer Overview
  • 9.5. Mycapssa® / (Chiasma Pharma)
    • 9.5.1. Drug Overview
    • 9.5.2. History of Development
    • 9.5.3. Mechanism of Action
    • 9.5.4. Manufacturing Information
    • 9.5.5. Current Status of Development
    • 9.5.6. Clinical Studies
    • 9.5.7. Key Clinical Trial Results
    • 9.5.8. Developer Overview
  • 9.6. ALLN-177 (Allena Pharmaceuticals)
  • 9.7. INN-202 (9 Meters Biopharma)
  • 9.8. ORMD-0801 (Oramed Pharmaceuticals)
  • 9.9. IN-105 (Biocon)
  • 9.10. Oral HDV Insulin (Diasome Pharmaceuticals)

10. CASE STUDIES: MINIRIN®, SANDIMMUNE® AND SOLLPURA®

  • 10.1. Chapter Overview
  • 10.2. Minirin® / DDAVP (Ferring Pharmaceuticals)
    • 10.2.1. Drug Overview
    • 10.2.2. History of Development
    • 10.2.3. Chemical Structure and Mechanism of Action
    • 10.2.4. Dosage Form, Treatment Regimen and Price
    • 10.2.5. Patent Portfolio
    • 10.2.6. Competitive Landscape
  • 10.3. Sandimmune® / Neoral® (Novartis)
    • 10.3.1. Drug Overview
    • 10.3.2. History of Development
    • 10.3.3. Mechanism of Action
    • 10.3.4. Dosage Form, Treatment Regimen and Price
    • 10.3.5. Patent Portfolio
    • 10.3.6. Competitive Landscape
  • 10.4. Sollpura® / Liprotamase (Anthera Pharmaceuticals)
    • 10.4.1. Drug Overview
    • 10.4.2. History of Development
    • 10.4.3. Chemical Structure and Mechanism of Action
    • 10.4.4. Current Status of Development
    • 10.4.5. Clinical Studies
    • 10.4.6. Competitive Landscape

11. ORAL PROTEIN / PEPTIDE DEVELOPMENT TECHNOLOGIES: MARKET LANDSCAPE

  • 11.1. Chapter Overview
  • 11.2. Oral Protein / Peptide Development Technologies: Market Landscape
    • 11.2.1. Analysis by Type of Technology
    • 11.2.2. Analysis by Compatible API Types
    • 11.2.3. Analysis by Target Therapeutic Area
    • 11.2.4. Analysis by Dosage Form
    • 11.2.5. Analysis by Status of Development of Products
  • 11.3. Oral Protein / Peptide Development Technologies: Developer Landscape
    • 11.3.1 Analysis by Year of Establishment
    • 11.3.2. Analysis by Company Size
    • 11.3.3 Analysis by Location of Headquarters
    • 11.3.4. Analysis by Company Size and Location of Headquarters

12. PRODUCT COMPETITIVENESS ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Product Competitiveness Analysis: Key Technologies

13. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS

  • 13.1. Chapter Overview
  • 13.2. Oral Drug Delivery: List of Technology Platforms
  • 13.3. Technology Profiles
    • 13.3.1. Axcess™ Oral Drug Delivery Technology (Proxima Concepts)
      • 13.3.1.1. Developer Overview
      • 13.3.1.2. Technology Overview
      • 13.3.1.3. Drug Delivery Mechanism
      • 13.3.1.4. Key Advantages
      • 13.3.1.5. Oral Proteins / Peptides Pipeline
      • 13.3.1.6. Collaborations
    • 13.3.2. Eligen™ Technology (Emisphere Technologies)
      • 13.3.2.1. Developer Overview
      • 13.3.2.2. Technology Overview
      • 13.3.2.3. Drug Delivery Mechanism
      • 13.3.2.4. Key Advantages
      • 13.3.2.5. Oral Proteins / Peptides Pipeline
      • 13.3.2.6. Collaborations
    • 13.3.3. Entera Technology (Entera Bio)
      • 13.3.3.1. Developer Overview
      • 13.3.3.2. Technology Overview
      • 13.3.3.3. Drug Delivery Mechanism
      • 13.3.3.4. Key Advantages
      • 13.3.3.5. Oral Proteins / Peptides Pipeline
    • 13.3.4. NTRA Oral Delivery Technology (Nutrinia)
      • 13.3.4.1. Developer Overview
      • 13.3.4.2. Technology Overview
      • 13.3.4.3. Drug Delivery Mechanism
      • 13.3.4.4. Key Advantages
      • 13.3.4.5. Oral Proteins / Peptides Pipeline
    • 13.3.5. Peptelligence® Technology (Enteris BioPharma)
      • 13.3.5.1. Developer Overview
      • 13.3.5.2. Technology Overview
      • 13.3.5.3. Drug Delivery Mechanism
      • 13.3.5.4. Key Advantages
      • 13.3.5.5. Oral Proteins / Peptides Pipeline
      • 13.3.5.6. Collaborations
    • 13.3.6. Protein Oral Delivery (POD™) Technology (Oramed Pharmaceuticals)
      • 13.3.6.1. Developer Overview
      • 13.3.6.2. Technology Overview
      • 13.3.6.3. Drug Delivery Mechanism
      • 13.3.6.4. Key Advantages
      • 13.3.6.5. Oral Proteins / Peptides Pipeline
    • 13.3.7. Transient Permeability Enhancer (TPE®) Technology (Chiasma Pharma)
      • 13.3.7.1. Developer Overview
      • 13.3.7.2. Technology Overview
      • 13.3.7.3. Drug Delivery Mechanism
      • 13.3.7.4. Key Advantages
      • 13.3.7.5. Oral Proteins / Peptides Pipeline
    • 13.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals)
      • 13.3.8.1. Developer Overview
      • 13.3.8.2. Technology Overview
      • 13.3.8.3. Drug Delivery Mechanism
      • 13.3.8.4. Key Advantages
      • 13.3.8.5. Oral Proteins / Peptides Pipeline

14. FUNDING AND INVESTMENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Types of Funding
  • 14.3. Oral Proteins / Peptides: Funding and Investment Analysis
    • 14.3.1. Analysis by Cumulative Number of Funding Instances
    • 14.3.2. Analysis by Cumulative Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Analysis by Year, Type of Funding and Amount Invested
    • 14.3.5. Analysis by Focus Area
    • 14.3.6. Analysis by Area of Application
    • 14.3.7. Analysis by Target Therapeutic Area
    • 14.3.8. Analysis by Geography
    • 14.3.9. Most Active Players: Analysis by Number of Instances
    • 14.3.10. Most Active Players: Analysis by Amount Invested
  • 14.4. Concluding Remarks

15. RECENT COLLABORATIONS

  • 15.1. Chapter Overview
  • 15.2. Partnership Models
  • 15.3. Oral Proteins / Peptides: Partnerships and Collaborations
    • 15.3.1. Analysis by Year of Partnership
    • 15.3.2. Analysis by Type of Partnership
    • 15.3.3. Analysis by Area of Application
    • 15.3.4. Analysis by Type of Partner
    • 15.3.5. Analysis by Focus Area
    • 15.3.6. Analysis by Target Therapeutic Area
    • 15.3.7. Most Active Players: Analysis by Number of Partnerships
    • 15.3.8. Analysis by Geography
    • 15.3.9. Intercontinental and Intracontinental Agreements

16. PUBLICATION ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Oral Proteins / Peptides: List of Publications
    • 16.2.1. Analysis by Year of Publication
    • 16.2.2. Analysis by Type of Molecule
    • 16.2.3. Analysis by Target Therapeutic Area
    • 16.2.4. Word Cloud of Study Titles
    • 16.2.5. Most Prominent Journals: Analysis by Number of Publications
    • 16.2.6. Most Prominent Authors: Analysis by Number of Publications

17. CLINICAL TRIAL ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Scope and Methodology
  • 17.3. Oral Protein / Peptide Therapeutics: Clinical Trial Analysis
    • 17.3.1. Analysis by Trial Registration Year
    • 17.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 17.3.3. Analysis by Trial Status
    • 17.3.4. Analysis by Trial Phase
    • 17.3.5. Analysis by Trial Registration Year and Trial Status
    • 17.3.6. Analysis by Enrolled Patient Population and Trial Phase
    • 17.3.7. Analysis by Type of Sponsor / Collaborator
    • 17.3.8. Analysis by Patient Segment
    • 17.3.9. Analysis by Target Therapeutic Area
    • 17.3.10. Analysis by Study Design
    • 17.3.11. Most Active Players: Analysis by Number of Registered Trials
    • 17.3.12. Analysis by Number of Trials and Geographical Location
    • 17.3.13. Analysis by Number of Trials, Trial Status and Geographical Location
    • 17.3.14. Analysis by Enrolled Patient Population and Trial Status

18. PATENT ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Scope and Methodology
  • 18.3. Oral Protein / Peptide Therapeutics: Patent Analysis
    • 18.3.1. Analysis by Publication Year
    • 18.3.2. Analysis by Patent Jurisdiction
    • 18.3.3. Analysis by Legal Status
    • 18.3.4. Analysis by CPC Symbols
    • 18.3.5. Emerging Focus Areas
    • 18.3.6. Analysis by Type of Applicant
    • 18.3.7. Leading Players: Analysis by Number of Patents
    • 18.3.8. Key Inventors: Analysis by Number of Patents
  • 18.4. Oral Protein / Peptide Therapeutics: Patent Benchmarking Analysis
    • 18.4.1. Analysis by Patent Characteristics
    • 18.4.2. Analysis by Geography
  • 18.5. Oral Protein / Peptide Therapeutics: Patent Valuation Analysis

19. BIG PHARMA ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Oral Protein / Peptide Therapeutics: Big Pharma Initiatives
    • 19.3.1. Analysis by Target Therapeutic Area
    • 19.3.2. Analysis by Type of Initiative
    • 19.3.3. Big Pharma Players: Benchmarking Analysis

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 20.1. Chapter Overview
  • 20.2. Scope and Limitations
  • 20.3. Forecast Methodology
  • 20.4. Global Oral Protein / Peptide Therapy Market, 2022-2032
    • 20.4.1. Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication
    • 20.4.2. Oral Protein / Peptide Therapy Market: Distribution by Type of Molecule
    • 20.4.3. Oral Protein / Peptide Therapy Market: Distribution by Technology Platform
    • 20.4.4. Oral Protein / Peptide Therapy Market: Distribution by Biological Target
    • 20.4.5. Oral Protein / Peptide Therapy Market: Distribution by Mechanism of Action
    • 20.4.6. Oral Protein / Peptide Therapy Market: Distribution by Key Players
    • 20.4.7. Oral Protein / Peptide Therapy Market: Distribution by Geography
  • 20.5. Oral Proteins / Peptides Market: Product-wise Sales Forecasts
    • 20.5.1. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
      • 20.5.1.1. Target Patient Population
      • 20.5.1.2. Sales Forecast
    • 20.5.2. Trulance® / Plecanatide (Synergy Pharmaceuticals)
      • 20.5.2.1. Target Patient Population
      • 20.5.2.2. Sales Forecast
    • 20.5.3. Mycapssa® / Octreolin (Chiasma Pharma)
      • 20.5.3.1. Target Patient Population
      • 20.5.3.2. Sales Forecast
    • 20.5.4. ALLN-177 (Allena Pharmaceuticals)
      • 20.5.4.1. Target Patient Population
      • 20.5.4.2. Sales Forecast
    • 20.5.5. Larazotide INN-202 (Innovate Biopharmaceuticals)
      • 20.5.5.1. Target Patient Population
      • 20.5.5.2. Sales Forecast
    • 20.5.6. Oral HDV Insulin (Diasome Pharmaceuticals)
      • 20.5.6.1. Target Patient Population
      • 20.5.6.2. Sales Forecast
    • 20.5.7. ORMD-0801 (Oramed Pharmaceuticals)
      • 20.5.7.1. Target Patient Population
      • 20.5.7.2. Sales Forecast
    • 20.5.8. IN-105 / Insulin Tregopil (Biocon)
      • 20.5.8.1. Target Patient Population
      • 20.5.8.2. Sales Forecast

21. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING

  • 21.1. Chapter Overview
  • 21.2. Key Steps Involved in Protein / Peptide Manufacturing
  • 21.3. Challenges Associated with Protein / Peptide Manufacturing
  • 21.4. Current Scenario of Protein / Peptide Manufacturing
  • 21.5. Growing Demand for Contract Manufacturing
    • 21.5.1. Selecting A Suitable CMO Partner
    • 21.5.2. Protein / Peptide CMOs: Market Landscape
      • 21.5.2.1. Analysis by Year of Establishment
      • 21.5.2.2. Analysis by Company Size
      • 21.5.2.3. Analysis by Location of Headquarters

22. KEY COMMERCIALIZATION / LIFECYCLE MANAGEMENT STRATEGIES

  • 22.1. Successful Drug Launch Strategy: ROOTS Framework
  • 22.2. Successful Drug Launch Strategy: Product Differentiation
  • 22.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
  • 22.4. Key Commercialization / Lifecycle Management Strategies Adopted by Companies Focused on Oral Protein / Peptide Therapeutics
    • 22.4.1. Strategies Adopted Before Therapy Approval
  • 22.5. Strategies Adopted During / Post Therapy Approval
  • 22.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

23. SWOT ANALYSIS

  • 23.1. Chapter Overview
  • 23.2. Comparison of SWOT Factors

24. CONCLUSION

  • 24.1 Chapter Overview

25. EXECUTIVE INSIGHTS

  • 25.1. Chapter Overview
  • 25.2. Anthera Pharmaceuticals
    • 25.2.1. Company Snapshot
    • 25.2.2. Interview Transcript: Dinesh Srinivasan, Director
  • 25.3. Carmot Therapeutics
    • 25.3.1. Company Snapshot
    • 25.3.2. Interview Transcript: Stig K Hansen, CEO
  • 25.4. IGY Life Sciences and Technology
    • 25.4.1. Company Snapshot
    • 25.4.2. Interview Transcript: Terry Dyck, President and CEO
  • 25.5. Constant Therapeutics
    • 25.5.1. Company Snapshot
    • 25.5.2. Interview Transcript: Richard Franklin, CEO

26. APPENDIX 1: RECENT DEVELOPMENTS

27. APPENDIX 2: TABULATED DATA

28. APPENDIX 3: LIST OF COMPANIES

List Of Figures

  • Figure 2.1 Executive Summary: Pipeline Overview
  • Figure 2.2 Executive Summary: KOL Analysis
  • Figure 2.3 Executive Summary: Drug Development Technology Providers Landscape
  • Figure 2.4 Executive Summary: Funding and Investment Analysis
  • Figure 2.5 Executive Summary: Partnerships and Collaborations
  • Figure 2.6 Executive Summary: Publication Analysis
  • Figure 2.7 Executive Summary: Clinical Trial Analysis
  • Figure 2.8 Executive Summary: Patent Analysis
  • Figure 2.9 Executive Summary: Big Pharma Analysis
  • Figure 2.10 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Comparison of Key Characteristics of Biologics and Small Molecules
  • Figure 3.2 Classification of Proteins
  • Figure 3.3 Routes of Administration for Proteins / Peptides
  • Figure 3.4 Drug Delivery: Distribution by Route of Administration
  • Figure 3.5 Mechanisms of Drug Transport through the Intestinal Epithelium
  • Figure 3.6 Mechanisms of Drug Transport through the Intestinal Epithelium via Attachment of Absorption Enhancers
  • Figure 3.7 Mechanisms of Drug Transport through the Intestinal Epithelium via Pro Drug Approach
  • Figure 3.8 Mechanisms of Drug Transport through the Intestinal Epithelium via Attachment of Enzyme Inhibitors
  • Figure 4.1 Oral Protein / Peptide Therapeutics: Distribution by Type of Molecule
  • Figure 4.2 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development
  • Figure 4.3 Oral Protein / Peptide Therapeutics: Distribution by Target Therapeutic Area
  • Figure 4.4 Oral Protein / Peptide Therapeutics: Distribution by Biological Target
  • Figure 4.5 Oral Protein / Peptide Therapeutics: Distribution by Mechanism of Action
  • Figure 4.6 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development and Mechanism of Action
  • Figure 4.7 Oral Protein / Peptide Therapeutics: Distribution by Number of Amino Acids
  • Figure 4.8 Key Drug Development Platforms: Distribution by Number of Products
  • Figure 4.9 Oral Protein / Peptide Therapeutics Developers: Distribution by Year of Establishment
  • Figure 4.10 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size
  • Figure 4.11 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.12 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.13 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
  • Figure 4.14 Most Active Players: Distribution by Number of Pipeline Candidates
  • Figure 4.15 Most Active Players: Distribution by Phase of Development
  • Figure 5.1 Oral Protein / Peptide Therapy Developers: Competitiveness Analysis
  • Figure 6.1 Oral Proteins / Peptides: Distribution by Therapeutic Area, Type of Molecule and Phase of Development (Grid Analysis)
  • Figure 6.2 Oral Proteins / Peptides Developer Landscape: Distribution by Company Size and Phase of Development
  • Figure 6.3 Oral Proteins / Peptides Regional Landscape (Industry Players): Distribution by Location of Headquarters and Pipeline Strength
  • Figure 7.1 KOL Analysis: Distribution by Type of Current Organization
  • Figure 7.2 KOL Analysis: Distribution by Geography
  • Figure 7.3 KOL Analysis: Distribution by Region (Continent-wise)
  • Figure 7.4 KOL Analysis: Distribution by Region (Country-wise)
  • Figure 7.5 KOL Analysis: Distribution by Number of Investigators and Current Organization
  • Figure 7.6 KOL Analysis: Distribution by Qualification of KOL
  • Figure 7.7 Comparison of KOL Activeness v/s Strength (Scatter Plot)
  • Figure 7.8 Comparison of Roots Analysis Score v/s Third Party Score
  • Figure 7.9 Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
  • Figure 7.10 Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
  • Figure 8.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
  • Figure 8.2 Non-Insulin Therapies for Diabetes
  • Figure 9.1 Linzess®: History of Development
  • Figure 9.2 Linzess®: Historical Sales, 2015-2020 (USD Million)
  • Figure 9.3 Trulance®: History of Development
  • Figure 9.4 TBRIA®: History of Development
  • Figure 9.5 Mycapssa®: History of Development
  • Figure 11.1 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology
  • Figure 11.2 Oral Protein / Peptide Development Technologies: Distribution by Compatible API Types
  • Figure 11.3 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology and Compatible API Types
  • Figure 11.4 Oral Protein / Peptide Development Technologies: Distribution by Target Therapeutic Area
  • Figure 11.5 Oral Protein / Peptide Development Technologies: Distribution by Dosage Form
  • Figure 11.6 Oral Protein / Peptide Development Technologies: Distribution by Status of Development of Products
  • Figure 11.7 Oral Protein / Peptide Development Technology Developers: Distribution by Year of Establishment
  • Figure 11.8 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size
  • Figure 11.9 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Region-wise)
  • Figure 11.10 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Country-wise)
  • Figure 11.11 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
  • Figure 12.1 Oral Protein / Peptide Development Technologies: Competitiveness Analysis
  • Figure 14.1 Funding and Investment Analysis: Cumulative Distribution by Number of Funding Instances
  • Figure 14.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million)
  • Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 14.5 Funding and Investment Analysis: Summary of Amount Invested
  • Figure 14.6 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million)
  • Figure 14.7 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
  • Figure 14.8 Funding and Investment Analysis: Distribution of Amount Invested by Area of Application (USD Million)
  • Figure 14.9 Funding and Investment Analysis: Distribution of Number of Instances by Target Therapeutic Area
  • Figure 14.10 Funding and Investment Analysis: Distribution of Amount Invested by Target Therapeutic Area (USD Million)
  • Figure 14.11 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Figure 14.12 Funding and Investment Analysis: Regional Distribution by Total Amount Invested (USD Million)
  • Figure 14.13 Most Active Players: Distribution by Number of Instances
  • Figure 14.14 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 14.15 Funding and Investment Analysis: Concluding Remarks
  • Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Distribution
  • Figure 15.2 Partnerships and Collaborations: Distribution by Type of Agreement
  • Figure 15.3 Partnerships and Collaborations: Distribution by Area of Application
  • Figure 15.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Agreement
  • Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 15.7 Partnerships and Collaborations: Distribution by Focus Area
  • Figure 15.8 Partnerships and Collaborations: Distribution by Target Therapeutic Area
  • Figure 15.9 Most Active Players: Distribution by Number of Partnerships
  • Figure 15.10 Partnerships and Collaborations: Geographical Distribution
  • Figure 15.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 16.1 Publication Analysis: Cumulative Year-wise Trend
  • Figure 16.2 Publication Analysis: Distribution by Type of Molecule
  • Figure 16.3 Publication Analysis: Distribution by Target Therapeutic Area
  • Figure 16.4 Publication Analysis: Word Cloud of Study Titles
  • Figure 16.5 Most Prominent Journals: Distribution by Number of Publications
  • Figure 16.6 Most Prominent Authors: Distribution by Number of Publications
  • Figure 17.1 Clinical Trial Analysis: Methodology
  • Figure 17.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
  • Figure 17.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
  • Figure 17.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 17.5 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 17.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 17.7 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
  • Figure 17.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 17.9 Clinical Trial Analysis: Distribution by Patient Segment
  • Figure 17.10 Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Figure 17.11 Clinical Trial Analysis: Distribution by Study Design
  • Figure 17.12 Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 17.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 17.14 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geographical Location
  • Figure 17.15 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geographical Location
  • Figure 17.16 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Status
  • Figure 18.1 Patent Analysis: Distribution by Type of Patent
  • Figure 18.2 Patent Analysis: Cumulative Distribution by Publication Year
  • Figure 18.3 Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 18.4 Patent Analysis: Distribution by Legal Status
  • Figure 18.5 Patent Analysis: Distribution by CPC Symbols
  • Figure 18.6 Patent Analysis: Emerging Focus Areas
  • Figure 18.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
  • Figure 18.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 18.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 18.10 Leading Industry Players: Distribution by International Patents
  • Figure 18.11 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 18.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
  • Figure 18.13 Patent Analysis: Distribution of Patents by Age
  • Figure 18.14 Oral Protein / Peptide Therapeutics: Patent Valuation
  • Figure 19.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
  • Figure 19.2 Big Pharma Players: Benchmarking Analysis
  • Figure 20.1 Global Oral Protein / Peptide Therapy Market, 2022-2032 (USD Million)
  • Figure 20.2 Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication, 2022, 2025 and 2032 (USD Million)
  • Figure 20.3 Oral Proteins / Peptide Therapy Market: Distribution by Type of Molecule, 2022, 2025 and 2032 (USD Million)
  • Figure 20.4 Oral Proteins / Peptide Therapy Market: Distribution by Technology Platform, 2022, 2025 and 2032 (USD Million)
  • Figure 20.5 Oral Proteins / Peptide Therapy Market: Distribution by Biological Target, 2022, 2025 and 2032 (USD Million)
  • Figure 20.6 Oral Proteins / Peptide Therapy Market: Distribution by Mechanism of Action, 2022, 2025 and 2032 (USD Million)
  • Figure 20.7 Oral Proteins / Peptide Therapy Market: Distribution by Key Players, 2022, 2025 and 2032 (USD Million)
  • Figure 20.8 Oral Protein / Peptide Therapy Market: Distribution by Geography 2022 and 2032 (USD Million)
  • Figure 20.9 Linzess® (Ironwood Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Figure 20.10 Trulance® (Bausch Health Sciences): Estimated Sales, 2022-2032 (USD Million)
  • Figure 20.11 Mycapssa® (Chiasma): Estimated Sales, 2022-2032 (USD Million)
  • Figure 20.12 ALLN-177 (Allena Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Figure 20.13 INN-202 (9 Meters Biopharma): Estimated Sales, 2022-2032 (USD Million)
  • Figure 20.14 Oral HDV Insulin (Diasome Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Figure 20.15 ORMD-0801 (Oramed Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Figure 20.16 IN-105 (Biocon): Estimated Sales, 2022-2032 (USD Million)
  • Figure 21.1 Key Steps Involved in the Manufacturing of Biologics
  • Figure 21.2 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2017)
  • Figure 21.3 Factors for Selecting a CMO Partner
  • Figure 21.4 Protein / Peptide Manufacturers: Distribution by Year of Establishment
  • Figure 21.5 Protein / Peptide Manufacturers: Distribution by Company Size
  • Figure 21.6 Protein / Peptide Manufacturers: Distribution by Location of Headquarters
  • Figure 22.1 Key Commercialization Strategies: Harvey Ball Analysis
  • Figure 22.2 Successful Drug Launch Strategy: ROOTS Framework
  • Figure 22.3 Successful Drug Launch Strategy: Product Differentiation
  • Figure 22.4 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
  • Figure 22.5 Harvey Ball Analysis: Commercialization Strategies Adopted by Oral Protein / Peptide Therapy Developers
  • Figure 23.1 Oral Proteins / Peptides SWOT Analysis: Overview
  • Figure 23.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 24.1 Concluding Remarks: Pipeline Overview
  • Figure 24.2 Concluding Remarks: KOL Analysis
  • Figure 24.3 Concluding Remarks: Drug Development Technology Providers Landscape
  • Figure 24.4 Concluding Remarks: Funding and Investment Analysis
  • Figure 24.5 Concluding Remarks: Partnerships and Collaborations
  • Figure 24.6 Concluding Remarks: Publication Analysis
  • Figure 24.7 Concluding Remarks: Clinical Trial Analysis
  • Figure 24.8 Concluding Remarks: Patent Analysis
  • Figure 24.9 Concluding Remarks: Big Pharma Analysis
  • Figure 24.10 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

  • Table 3.1 Comparison of Key Routes of Delivery
  • Table 4.1 Oral Proteins / Peptide Therapeutics: Drug Pipeline
  • Table 4.2 Oral Proteins / Peptide Therapeutics: Information on Disease Indication, Target Therapeutic Area, Biological Target and Mechanism of Action
  • Table 4.3 Oral Proteins / Peptide Therapeutics: Information on Number of Amino Acids and Platform Used for Development
  • Table 4.4 Oral Proteins / Peptide Therapy Developers: Information on Year of Establishment, Employee Count, Company Size and Headquarters
  • Table 4.5 Oral Proteins / Peptide Therapeutics: Other Drugs
  • Table 7.1 Oral Proteins / Peptide Therapeutics: Principal Investigators
  • Table 8.1 Diabetes: Current Treatment Options
  • Table 8.2 Diabetes: Side Effects of Current Treatment Options
  • Table 8.3 Diabetes: Oral Proteins / Peptides Pipeline
  • Table 8.4 Obesity: Side Effects of Current Treatment Options
  • Table 8.5 Obesity: Oral Proteins / Peptides Pipeline
  • Table 8.6 NASH: Oral Proteins / Peptides Pipeline
  • Table 8.7 Ulcerative Colitis: Current Treatment Options
  • Table 8.8 Ulcerative Colitis: Side Effects of Current Treatment Options
  • Table 8.9 Ulcerative Colitis: Oral Proteins / Peptides Pipeline
  • Table 8.10 Crohn's Disease: Current Treatment Options
  • Table 8.11 Crohn's Disease: Side Effects of Current Treatment Options
  • Table 8.12 Crohn's Disease: Oral Proteins / Peptides Pipeline
  • Table 8.13 CDIs: Diagnostic Testing
  • Table 8.14 CDIs: Severity Scoring System and Treatment Options
  • Table 8.15 CDIs: Side Effects of Current Treatment Options
  • Table 8.16 CDIs: Oral Proteins / Peptides Pipeline
  • Table 8.17 Celiac Disease: Oral Proteins / Peptides Pipeline
  • Table 8.18 Acromegaly: Current Treatment Options
  • Table 8.19 Acromegaly: Side Effects of Current Treatment Options
  • Table 8.20 Acromegaly: Oral Proteins / Peptides Pipeline
  • Table 8.21 Osteoporosis: Current Treatment Options
  • Table 8.22 Osteoporosis: Side Effects of Current Treatment Options
  • Table 8.23 Osteoporosis: Oral Proteins / Peptides Pipeline
  • Table 9.1 Oral Peptides / Proteins: List of Drugs Profiled
  • Table 9.2 Linzess®: Dosage Details
  • Table 9.3 Linzess®: Current Status of Development
  • Table 9.4 Linzess®: Clinical Trials
  • Table 9.5 Linzess®: Results of Phase III Clinical Trial for CIC
  • Table 9.6 Ironwood Pharmaceuticals: Key Highlights
  • Table 9.7 Trulance®: Current Status of Development
  • Table 9.8 Trulance®: Clinical Trials
  • Table 9.9 Salix Pharmaceuticals: Key Highlights
  • Table 9.10 TBRIA™: Current Status of Development
  • Table 9.11 TBRIA™: Clinical Trials
  • Table 9.12 TBRIA™: Results of Phase III ORACAL Clinical Trial
  • Table 9.13 Tarsa Therapeutics: Key Highlights
  • Table 9.14 Mycapssa®: Current Status of Development
  • Table 9.15 Mycapssa®: Clinical Trials
  • Table 9.16 Mycapssa®: Results of Phase III Clinical Trial for Acromegaly
  • Table 9.17 Chiasma Pharma: Key Highlights
  • Table 9.18 Drug Profile: ALLN-177
  • Table 9.19 Drug Profile: INN-202
  • Table 9.20 Drug Profile: ORMD-0801
  • Table 9.21 Drug Profile: IN-105
  • Table 9.22 Drug Profile: Oral HDV Insulin
  • Table 10.1 Oral Proteins / Peptides: List of Other Associated Drugs
  • Table 10.2 Minirin®: Generic Versions
  • Table 10.3 Minirin®: Dosage Details
  • Table 10.4 Minirin®: Price of Tablets
  • Table 10.5 Minirin®: Patent Portfolio
  • Table 10.6 Minirin®: Competitive Landscape
  • Table 10.7 Sandimmune® / Neoral®: Generic Versions
  • Table 10.8 Sandimmune® / Neoral®: Dosage Details
  • Table 10.9 Neoral®: Patent Portfolio
  • Table 10.10 Sandimmune® / Neoral®: Competitive Landscape
  • Table 10.11 Sollpura®: Mechanism of Action
  • Table 10.12 Sollpura®: Current Status of Development
  • Table 10.13 Sollpura®: Clinical Trials
  • Table 10.14 Sollpura®: Current Treatment Options
  • Table 11.1 Oral Protein / Peptide Therapy Development Technologies: Information on Type of Technology, Compatible API Types, Number of Development Programs
  • Table 11.2 Oral Protein / Peptide Therapy Development Technologies: Information on Target Therapeutic Area and Dosage Form
  • Table 11.3 Oral Protein / Peptide Therapy Development Technology Developers: Information on Year of Establishment, Employee Count, Company Size and Headquarters
  • Table 13.1 Oral Delivery Technology Platforms: Comparison of Key Features
  • Table 13.2 Oral Delivery Technology Platforms: Clinical Stages of Development
  • Table 13.3 Axcess™ Technology: Oral Proteins / Peptides Pipeline
  • Table 13.4 Eligen™ Technology: Oral Proteins / Peptides Pipeline
  • Table 13.5 Entera Technology: Oral Proteins / Peptides Pipeline
  • Table 13.6 NTRA Oral Delivery Technology: Oral Proteins / Peptides Pipeline
  • Table 13.7 Peptelligence® Technology: Oral Proteins / Peptides Pipeline
  • Table 13.8 POD™ Technology: Oral Proteins / Peptides Pipeline
  • Table 13.9 TPE® Technology: Oral Proteins / Peptides Pipeline
  • Table 13.10 Uroguanylin Analogue Platform: Oral Proteins / Peptides Pipeline
  • Table 14.1 Oral Proteins / Peptides: Funding and Investment Analysis
  • Table 14.2 Oral Proteins / Peptides: Summary of Investments
  • Table 15.1 Oral Proteins / Peptides: Recent Partnerships
  • Table 16.1 Oral Proteins / Peptides: List of Publications
  • Table 18.1 Patent Analysis: CPC Symbols
  • Table 18.2 Patent Analysis: Most Popular CPC Symbols
  • Table 18.3 Patent Analysis: List of Top 10 CPC Symbols
  • Table 18.4 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 18.5 Patent Analysis: List of Relatively Higher Value Patents
  • Table 20.1 Oral Proteins / Peptides Market: Potential Candidates
  • Table 20.2 Oral Proteins / Peptides Forecast Assumptions: Price Estimation in Key Geographies
  • Table 20.3 Oral Proteins / Peptides Forecast Assumptions: Growth Rate Estimation by Key Indications
  • Table 20.4 Linzess®: Target Patient Population
  • Table 20.5 Trulance®: Target Patient Population
  • Table 20.6 Mycapssa®: Target Patient Population
  • Table 20.7 ALLN-177: Target Patient Population
  • Table 20.8 Larazotide INN-202: Target Patient Population
  • Table 20.9 Oral HDV Insulin: Target Patient Population
  • Table 20.10 ORMD-0801: Target Patient Population
  • Table 20.11 IN-105: Target Patient Population
  • Table 21.1 List of Contract Manufacturers Involved in Proteins / Peptides Manufacturing
  • Table 22.1 Oral Protein / Peptide Therapeutics: Key Commercialization / Lifecycle Management Strategies
  • Table 25.1 Anthera Pharmaceuticals: Key Highlights
  • Table 25.2 Carmot Therapeutics: Key Highlights
  • Table 25.3 IGY Life Sciences and Technology: Key Highlights
  • Table 25.4 Constant Therapeutics: Key Highlights
  • Table 26.1 Oral Protein / Peptide Therapeutics: Distribution by Type of Molecule
  • Table 26.2 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development
  • Table 26.3 Oral Protein / Peptide Therapeutics: Distribution by Target Therapeutic Area
  • Table 26.4 Oral Protein / Peptide Therapeutics: Distribution by Biological Target
  • Table 26.5 Oral Protein / Peptide Therapeutics: Distribution by Mechanism of Action
  • Table 26.6 Oral Protein / Peptide Therapeutics: Distribution by Phase of Development and Mechanism of Action
  • Table 26.7 Oral Protein / Peptide Therapeutics: Distribution by Number of Amino Acids
  • Table 26.8 Key Drug Development Platforms: Distribution by Number of Products
  • Table 26.9 Oral Protein / Peptide Therapeutics Developers: Distribution by Year of Establishment
  • Table 26.10 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size
  • Table 26.11 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Region-wise)
  • Table 26.12 Oral Protein / Peptide Therapeutics Developers: Distribution by Location of Headquarters (Country-wise)
  • Table 26.13 Oral Protein / Peptide Therapeutics Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
  • Table 26.14 Most Active Players: Distribution by Number of Pipeline Candidates
  • Table 26.15 Most Active Players: Distribution by Phase of Development
  • Table 26.16 KOL Analysis: Distribution by Type of Current Organization
  • Table 26.17 KOL Analysis: Distribution by Geography
  • Table 26.18 Linzess®: Historical Sales, 2015-2020 (USD Million)
  • Table 26.19 Oral Protein / Peptide Development Technologies: Distribution by Type of Technology
  • Table 26.20 Oral Protein / Peptide Development Technologies: Distribution by Compatible API Types
  • Table 26.21 Oral Protein / Peptide Development Technologies: Distribution by Target Therapeutic Area
  • Table 26.22 Oral Protein / Peptide Development Technology Developers: Distribution by Year of Establishment
  • Table 26.23 Oral Protein / Peptide Development Technology Developers: Distribution by Company Size
  • Table 26.24 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Region-wise)
  • Table 26.25 Oral Protein / Peptide Development Technology Developers: Distribution by Location of Headquarters (Country-wise)
  • Table 26.26 Oral Protein / Peptide Development Technologies: Competitiveness Analysis
  • Table 26.27 Funding and Investment Analysis: Cumulative Distribution by Number of Funding Instances
  • Table 26.28 Funding and Investment Analysis: Cumulative Amount Invested (USD Million)
  • Table 26.29 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Table 26.30 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 26.31 Funding and Investment Analysis: Summary of Amount Invested
  • Table 26.32 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million)
  • Table 26.33 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
  • Table 26.34 Funding and Investment Analysis: Distribution of Amount Invested by Area of Application (USD Million)
  • Table 26.35 Funding and Investment Analysis: Distribution of Number of Instances by Target Therapeutic Area
  • Table 26.36 Funding and Investment Analysis: Distribution of Amount Invested by Target Therapeutic Area (USD Million)
  • Table 26.37 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Table 26.38 Funding and Investment Analysis: Regional Distribution by Total Amount Invested (USD Million)
  • Table 26.39 Most Active Players: Distribution by Number of Instances
  • Table 26.40 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 26.41 Partnerships and Collaborations: Cumulative Year-wise Distribution
  • Table 26.42 Partnerships and Collaborations: Distribution by Type of Agreement
  • Table 26.43 Partnerships and Collaborations: Distribution by Area of Application
  • Table 26.44 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 26.45 Partnerships and Collaborations: Distribution by Focus Area
  • Table 26.46 Partnerships and Collaborations: Distribution by Target Therapeutic Area
  • Table 26.47 Most Active Players: Distribution by Number of Partnerships
  • Table 26.48 Partnerships and Collaborations: Geographical Distribution
  • Table 26.49 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 26.50 Publication Analysis: Cumulative Year-wise Trend
  • Table 26.51 Publication Analysis: Distribution by Type of Molecule
  • Table 26.52 Publication Analysis: Distribution by Target Therapeutic Area
  • Table 26.53 Most Prominent Journals: Distribution by Number of Publications
  • Table 26.54 Most Prominent Authors: Distribution by Number of Publications
  • Table 26.55 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
  • Table 26.56 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient population
  • Table 26.57 Clinical Trial Analysis: Distribution by Trial Status
  • Table 26.58 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 26.59 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 26.60 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
  • Table 26.61 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 26.62 Clinical Trial Analysis: Distribution by Patient Segment
  • Table 26.63 Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Table 26.64 Clinical Trial Analysis: Distribution by Study Design
  • Table 26.65 Most Active Industry Players: Distribution by Number of Registered Trials
  • Table 26.66 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 26.67 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geographical Location
  • Table 26.68 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geographical Location
  • Table 26.69 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status
  • Table 26.70 Patent Analysis: Distribution by Type of Patent
  • Table 26.71 Patent Analysis: Cumulative Distribution by Publication Year
  • Table 26.72 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 26.73 Patent Analysis: Distribution by Legal Status
  • Table 26.74 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
  • Table 26.75 Leading Industry Players: Distribution by Number of Patents
  • Table 26.76 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 26.77 Leading Industry Players: Distribution by International Patents
  • Table 26.78 Leading Patent Assignees: Distribution by Number of Patents
  • Table 26.79 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
  • Table 26.80 Patent Analysis: Distribution of Patents by Age
  • Table 26.81 Oral Protein / Peptide Therapeutics: Patent Valuation
  • Table 26.82 Overall Oral Proteins / Peptide Therapy Market, 2022-2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.83 Oral Proteins / Peptide Therapy Market: Distribution by Target Disease Indication, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.84 Oral Proteins / Peptide Therapy Market: Distribution by Type of Molecule, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.85 Oral Proteins / Peptide Therapy Market: Distribution by Technology Platforms, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.86 Oral Proteins / Peptide Therapy Market: Distribution by Biological Target, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.87 Oral Proteins / Peptide Therapy Market: Distribution by Mechanism of Action, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.88 Oral Proteins / Peptide Therapy Market: Distribution by Key Players, 2022, 2025 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.89 Oral Proteins / Peptide Therapy Market: Distribution by Geography 2022 and 2032, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.90 Linzess® (Ironwood Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.91 Trulance® (Bausch Health Sciences): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.92 Mycapssa® (Chiasma): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.93 ALLN-177 (Allena Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.94 INN-202 (9 Meters Biopharma): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.95 Oral HDV Insulin (Diasome Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.96 ORMD-0801 (Oramed Pharmaceuticals): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.97 IN-105 (Biocon): Estimated Sales, 2022-2032 (USD Million)
  • Table 26.98 Approval Trend for Small Molecule and Large Molecule Drugs (2005-2020)
  • Table 26.99 Factors for Selecting a CMO Partner
  • Table 26.100 Protein / Peptide Manufacturers: Distribution by Year of Establishment
  • Table 26.101 Protein / Peptide Manufacturers: Distribution by Company Size
  • Table 26.102 Protein / Peptide Manufacturers: Distribution by Location of Headquarters

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. 7-Med Health Ventures
  • 3. 9 Meters Biopharma
  • 4. Aalto Scientific
  • 5. Abbott Laboratories
  • 6. AbbVie
  • 7. Abeona Therapeutics
  • 8. Abingworth
  • 9. ABL Venture Capital
  • 10. Abzena
  • 11. Access Pharmaceuticals
  • 12. ACES Pharma
  • 13. Acorn Biomedical
  • 14. ActoGeniX
  • 15. Adage Capital Management
  • 16. Adams Capital Management
  • 17. Adar Biotech
  • 18. Adcock Ingram
  • 19. Aegis Capital
  • 20. Aescap Venture
  • 21. Affilogic
  • 22. Affinity Life Sciences
  • 23. AIM ImmunoTech
  • 24. AIMM Therapeutics
  • 25. Ajinomoto Bio-Pharma Services
  • 26. Alaven Pharmaceutical
  • 27. Alba Therapeutics
  • 28. Albert Einstein Medical Center
  • 29. Albiochem
  • 30. Albireo Pharma
  • 31. Alcami
  • 32. Alchemia
  • 33. Aldevron
  • 34. Allena Pharmaceuticals
  • 35. Allergan
  • 36. Almac
  • 37. Almirall
  • 38. Alnara Pharmaceuticals
  • 39. Alphabet
  • 40. Alrov
  • 41. Alta Biopharma Partners
  • 42. Althea Technologies
  • 43. Altus Pharmaceuticals
  • 44. Alza Pharmaceuticals
  • 45. Amarillo Biosciences
  • 46. Amatsigroup
  • 47. AmatsiQBiologicals
  • 48. AmbioPharm
  • 49. Amerant Bancorp
  • 50. Amgen
  • 51. Anaheim Clinical Trials
  • 52. AnaSpec
  • 53. Anthera Pharmaceuticals
  • 54. Aphios
  • 55. Apotex
  • 56. Applied Molecular Transport
  • 57. Aptalis Pharma
  • 58. Aquestive Therapeutics
  • 59. Aravis Ventures
  • 60. ARCH Venture Partners
  • 61. Arena Pharmaceuticals
  • 62. Arisaph Pharmaceuticals
  • 63. ArisGen
  • 64. Armenian Development Agency
  • 65. Asahi Glass
  • 66. Ascendia Pharmaceuticals
  • 67. Ascent Biomedical Ventures
  • 68. Aspen Oss
  • 69. Assaf Harofeh Medical Center
  • 70. Assembly Biosciences
  • 71. Astellas Pharma
  • 72. AstraZeneca
  • 73. Asymchem
  • 74. Atara Technology Ventures
  • 75. Atlantic Peptides
  • 76. Atrix Laboratories
  • 77. Augusta University
  • 78. AURA Biotechnologies
  • 79. Aurigene Pharmaceutical Services
  • 80. Auspep
  • 81. Austin Chemical
  • 82. AutekBio
  • 83. Avaxia Biologics
  • 84. Avid Bioservices
  • 85. Avista Development
  • 86. Axcan Pharma
  • 87. AzurRx BioPharma
  • 88. Baccinex
  • 89. Bachem
  • 90. Baekeland Funds
  • 91. BAM Biotech
  • 92. Barr Pharmaceuticals
  • 93. Basque Regional Government
  • 94. Batavia Biosciences
  • 95. Bausch Health
  • 96. Baxter BioPharma Solutions
  • 97. Bayer
  • 98. BCN Peptides
  • 99. Beacon Angels
  • 100. BeiGene
  • 101. Beijing Friendship Hospital
  • 102. Beijing Tiantan Hospital
  • 103. Beijing Tongren Hospital
  • 104. Bessemer Venture Partners
  • 105. Beta Fund
  • 106. Bharat Serums and Vaccines
  • 107. Bill & Melinda Gates Foundation
  • 108. BIND Therapeutics
  • 109. BINEX
  • 110. Bio Elpida
  • 111. Bio Farma
  • 112. Biocell
  • 113. Biocon
  • 114. BioConnection
  • 115. Biodel
  • 116. BioEconomy Capital
  • 117. Biogen
  • 118. Bio-Kinetic Clinical Applications
  • 119. Biolaxy
  • 120. BioLingus
  • 121. Biological Process Development Facility (BPDF)
  • 122. Biomatik
  • 123. Biomay
  • 124. Biomedical Advanced Research and Development Authority (BARDA)
  • 125. Biopeptek Pharmaceuticals
  • 126. BioPharmaceuticals Australia
  • 127. Biosynergy
  • 128. Bio-Synthesis
  • 129. Biotech Fund Flanders
  • 130. BioTechLogic
  • 131. Biotechnology and Biological Sciences Research Council
  • 132. Biotechpharma
  • 133. Bio-Thera Solutions
  • 134. BioVectra
  • 135. BioVeda Capital
  • 136. Biovest
  • 137. Biovian
  • 138. Black Beret Life Sciences
  • 139. Blue Devil Trust
  • 140. Boehringer Ingelheim
  • 141. Bone Medical
  • 142. Bossa Ventures
  • 143. Boston Harbor Angels
  • 144. Botanix Pharmaceuticals
  • 145. Brigham and Women's Hospital
  • 146. Broadview Ventures
  • 147. Brown University
  • 148. Bumi Medic
  • 149. Burrard Pharmaceuticals
  • 150. Butler Hospital
  • 151. Buttonwood Financial
  • 152. BVF Partners
  • 153. BZ Bank
  • 154. Cadila Healthcare
  • 155. Calvert Research Institute
  • 156. Canaan Partners
  • 157. Canada Armenia Trading House
  • 158. Cancer Care Northwest
  • 159. Cancer Specialists of South Texas
  • 160. Cara Therapeutics
  • 161. CARBOGEN AMCIS
  • 162. CARB-X
  • 163. Cardinal Health
  • 164. Carmot Therapeutics
  • 165. Catalent
  • 166. Cathay Ventures
  • 167. CBL
  • 168. Cedars-Sinai Medical Center
  • 169. Celiac Disease Foundation
  • 170. Cell Culture Company
  • 171. Cell Culture Company (C3)
  • 172. Celltrion
  • 173. Celltrion Healthcare
  • 174. Celonic
  • 175. CEM
  • 176. Center for Biocatalysis and Bioprocessing (CBB)
  • 177. Century Pharmaceuticals
  • 178. Cerbios-Pharma
  • 179. Changhai Hospital
  • 180. Changzheng Hospital
  • 181. Chao Family Comprehensive Cancer Center
  • 182. Charles River Laboratories
  • 183. Chattem
  • 184. CHEMI
  • 185. ChemPartner
  • 186. Cherrystone Angels
  • 187. Chiasma
  • 188. Chicago Innovation Fund
  • 189. Chiesi Farmaceutici
  • 190. Children's Reserach Institute
  • 191. ChinaTech Peptide
  • 192. Chinese Peptide Company
  • 193. Chinese PLA General Hospital
  • 194. Chong Kun Dang Pharmaceutical
  • 195. Circle33
  • 196. Citizens Bank
  • 197. ClinSearch
  • 198. CNF Investments
  • 199. CNR Institute of Clinical Physiology
  • 200. Cobra Biologics
  • 201. Columbia University
  • 202. Connecticut Innovations
  • 203. Constant Therapeutics
  • 204. CordenPharma
  • 205. CoreMed
  • 206. Cosmo Pharmaceuticals
  • 207. Courtagen Life Sciences
  • 208. CPC Scientific
  • 209. Creative Peptides
  • 210. CreoSalus
  • 211. CRG
  • 212. Crystal Horizon Investments
  • 213. CSBio
  • 214. CureDM
  • 215. Curia
  • 216. Cystic Fibrosis Foundation Therapeutics
  • 217. CytoPharm
  • 218. Cytovance Biologics
  • 219. D.N.A Biomedical Solutions
  • 220. Dalton Pharma Services
  • 221. Dana-Farber Cancer Institute
  • 222. Danish Megatrend Invest
  • 223. Devon Park BioVentures
  • 224. Diabetology
  • 225. Diapin Therapeutics
  • 226. Diasome Pharmaceuticals
  • 227. Digestive Care
  • 228. DM Bio
  • 229. Docor International
  • 230. Dr. Falk Pharma
  • 231. Duke University
  • 232. Edward P. Bass Group
  • 233. EirGenix
  • 234. Elasmogen
  • 235. Eli Lilly
  • 236. Elite Research Institute
  • 237. Embio
  • 238. Emergent BioSolutions
  • 239. Emisphere Technologies
  • 240. Emory University
  • 241. Encap Drug Delivery
  • 242. Encorium Group
  • 243. enGene
  • 244. Engineered BioPharmaceuticals
  • 245. Engineering and Physical Sciences Research Council
  • 246. Entera Bio
  • 247. Enteris BioPharma
  • 248. Enterome Bioscience
  • 249. Entrega
  • 250. Enzene Biosciences
  • 251. EPQ
  • 252. Esperante Ventures
  • 253. Eti Karle Clinical
  • 254. EuBiologics
  • 255. EUCODIS Bioscience
  • 256. Eurogentec
  • 257. Europe Pharmaceutical
  • 258. European Biomedical Research Institute of Salerno (EBRIS)
  • 259. European Commission
  • 260. European Cystic Fibrosis Society
  • 261. European Medical Association
  • 262. Evonik Industries
  • 263. F2 Capital
  • 264. F3 Ventures
  • 265. Ferrer Internacional
  • 266. Ferring Pharmaceuticals
  • 267. Fidelity Management & Research Company
  • 268. FightMND
  • 269. Firebird Global Master Fund
  • 270. First Affiliated Hospital of Harbin Medical University
  • 271. Fondazione Centro San Raffaele del Monte Tabor
  • 272. Forbion Capital Partners
  • 273. Foresite Capital
  • 274. Forest Laboratories
  • 275. Founders Fund
  • 276. Frazier Healthcare Partners
  • 277. French Innovative Leukemia Organisation
  • 278. FUJIFILM Diosynth Biotechnologies
  • 279. Gala Biotech
  • 280. Galera Therapeutics
  • 281. GD Searle
  • 282. GE Healthcare
  • 283. General Hospital of Shenyang Military Region
  • 284. Generex Biotechnology
  • 285. GeneScience Pharmaceuticals
  • 286. GenIbet Biopharmaceuticals
  • 287. Genta
  • 288. GF Ventures
  • 289. GGV Capital
  • 290. Gila Therapeutics
  • 291. Gilead Sciences
  • 292. Gimv
  • 293. GlaxoSmithKline
  • 294. Glycotope Biotechnology
  • 295. Golden Seeds
  • 296. Goodwin Biotechnology
  • 297. GP Pharm
  • 298. Grand River Aseptic Manufacturing
  • 299. Granite State Angels
  • 300. Great Point Partners
  • 301. Grupo Espanol de Tumores Neuroendocrinos
  • 302. GTP Technology
  • 303. Guangzhou Medical University
  • 304. Gülhane Military Medical School
  • 305. GV
  • 306. H.I.G. BioHealth Partners
  • 307. Hadassah Medical Center
  • 308. HALIX
  • 309. Harvard Business School Angels
  • 310. Hayashibara Biochemical Laboratories
  • 311. HBG Beteiligungs- und Beratungsgesellschaft
  • 312. HBM BioCapital
  • 313. Health Biotech
  • 314. Healthcare Royalty Partners
  • 315. Hefei Tianhui Incubator of Technologies
  • 316. Hemispherx Biopharma
  • 317. Hepasome Pharmaceuticals
  • 318. Heptares Therapeutics
  • 319. Hetero Drugs
  • 320. Highbridge Capital
  • 321. High-Tech Gründerfonds
  • 322. Hoechst Marion Roussel
  • 323. Hong Kong Institute of Biotechnology
  • 324. Horizons Ventures
  • 325. Hovione
  • 326. Hybio Pharmaceutical
  • 327. iBio
  • 328. IDT Biologika
  • 329. IGY Life Sciences and Technology
  • 330. Immuron
  • 331. InCube Ventures
  • 332. Ingro Finanz
  • 333. Inno Biologics
  • 334. InnoMed Fund
  • 335. Innovate Biopharmaceuticals
  • 336. Intas Pharmaceuticals
  • 337. Integrity Bio
  • 338. Intract Pharma
  • 339. Intrexon
  • 340. Ippon Capital
  • 341. Ipsen Pharma
  • 342. Ironwood Pharmaceuticals
  • 343. iSelect Fund
  • 344. Istituto Biochimico Italiano Giovanni Lorenzini
  • 345. Ivax Pharmaceuticals
  • 346. Janssen Pharmaceuticals
  • 347. JMP Securities Stifel
  • 348. Johnson & Johnson
  • 349. Jordanian Pharmaceutical Manufacturing
  • 350. Joslin Diabetes Center
  • 351. Julphar
  • 352. Julphar Gulf Pharmaceutical Industries
  • 353. Juvenile Diabetes Research Foundation (JDRF)
  • 354. Kafrelsheikh University
  • 355. Kamat Pharmatech
  • 356. KareBay Biochem
  • 357. KBI Biopharma
  • 358. Kemwell Biopharma
  • 359. KeyBioscience
  • 360. Kinexus Bioinformatics
  • 361. King Hamad University Hospital
  • 362. KPC Pharmaceuticals
  • 363. KriSan Biotech
  • 364. Lakeland Regional Cancer Center
  • 365. LAMPIRE Biological Laboratories
  • 366. LaunchPad Venture Group
  • 367. Lexicon Pharmaceuticals
  • 368. LFB Biomanufacturing
  • 369. Life Sciences Partners
  • 370. Lilly Ventures
  • 371. Lobesity
  • 372. LODH Immunology Fund
  • 373. Longevity Biotech
  • 374. Longitude Capital
  • 375. Lonza
  • 376. LuinaBio
  • 377. Lumen Bioscience
  • 378. Lumira Capital
  • 379. Lundbeckfonden Ventures
  • 380. Lyfebulb
  • 381. Lyotex
  • 382. Madryn Asset Management
  • 383. Maine Angels
  • 384. Mallinckrodt Pharmaceuticals
  • 385. MannKind
  • 386. Marathon Capital Development Fund
  • 387. Maruishi Pharmaceutical Company
  • 388. Mass Medical Angels
  • 389. Massachusetts General Hospital
  • 390. Massachusetts Institute of Technology
  • 391. Maverick Capital
  • 392. Maxim Group
  • 393. Mayo Clinic
  • 394. McDonald Partners
  • 395. MD Anderson Cancer Center
  • 396. Medeva Pharmaceuticals
  • 397. Medicxi Ventures
  • 398. MedImmune
  • 399. Medizinische Klinik - Innenstadt
  • 400. Medpace
  • 401. Menarini Biotech
  • 402. Mentor Pharmaceuticals
  • 403. Merck
  • 404. Meridian Life Science
  • 405. Merrion Pharmaceuticals
  • 406. Merro Pharmaceutical
  • 407. MHR Fund Management
  • 408. MicroBiopharm Japan
  • 409. MidaSol Therapeutics
  • 410. Midatech Pharma
  • 411. MidCap Financial
  • 412. Millennium Pharmaceuticals
  • 413. Mitsubishi Tanabe Pharma
  • 414. Monash University
  • 415. Montaur Capital Partners
  • 416. More Investment House
  • 417. Morgan Stanley Investment Management
  • 418. MPM Capital
  • 419. MSD Partners
  • 420. MVM Life Science Partners
  • 421. Mylan
  • 422. NanoMega Medical
  • 423. National Cancer Institute
  • 424. National Institute of Allergy and Infectious Diseases
  • 425. National Institute of Diabetes and Digestive and Kidney Diseases
  • 426. National Institutes of Health
  • 427. National MS Society
  • 428. National Multiple Sclerosis Society
  • 429. Neodel Pharma
  • 430. Neuland Laboratories
  • 431. New Generation Technology
  • 432. New River Management
  • 433. NewVa Capital Partners
  • 434. Niagara University
  • 435. Nitto Avecia Pharma Services
  • 436. Nobex
  • 437. NOD Pharmaceuticals
  • 438. Nordic Biosciences
  • 439. Nordmark Arzneimittel
  • 440. Norwalk Hospital
  • 441. Nova Laboratories
  • 442. Novartis
  • 443. Novartis Venture Fund
  • 444. Novasep
  • 445. Novetide
  • 446. Novex
  • 447. Novimmune
  • 448. Novo Nordisk
  • 449. NSJ Prayog Life Science
  • 450. Nucleus Network
  • 451. NUMAFERM
  • 452. Nutrinia
  • 453. OctoPlus
  • 454. Ofer Hi-Tech Group
  • 455. Oklahoma Foundation for Digestive Research
  • 456. Olon
  • 457. Omnia Biologics
  • 458. Oragenics
  • 459. Oramed Pharmaceuticals
  • 460. Orange County Research Center
  • 461. OrbiMed
  • 462. Oregon Health & Science University
  • 463. Orexigen Therapeutics
  • 464. ORPEGEN Peptide Chemicals
  • 465. Oshadi Drug Administration
  • 466. Osmangazi University Medical School
  • 467. Oso Biopharmaceuticals Manufacturing
  • 468. OsoBio
  • 469. Oxalo Therapeutics
  • 470. Oxford Finance
  • 471. P&G Pharmaceuticals
  • 472. Pacific Venture Opportunity Fund
  • 473. Panacea Biotec
  • 474. Paperboy Ventures
  • 475. Paragon Bioservices
  • 476. Parexel
  • 477. Partner Fund Management
  • 478. Patheon
  • 479. Peking University First Hospital
  • 480. Pendopharm
  • 481. Pepceuticals
  • 482. Pepscan
  • 483. Peptide Institute
  • 484. PeptiStar
  • 485. Perceptive Advisors
  • 486. Pfanstiehl
  • 487. Pfizer
  • 488. Pharmacia & Upjohn
  • 489. Pharmstandard International
  • 490. piCHEM
  • 491. Pictet Private Equity Investors
  • 492. Pinemount Investments
  • 493. Ping An Ventures
  • 494. Piramal Pharma Solutions
  • 495. PlasmaTech Biopharmaceuticals
  • 496. PLIVA
  • 497. Polymun Scientific
  • 498. PolyPeptide
  • 499. Pontifax
  • 500. Praxis Pharmaceutical
  • 501. Precigen
  • 502. Precision BioSciences
  • 503. Premas Biotech
  • 504. Previtalica
  • 505. Priavoid
  • 506. PrimaPharma
  • 507. ProBioGen
  • 508. Productos Biologicos
  • 509. Profil Institut für Stoffwechselforschung
  • 510. ProJect Pharmaceutics
  • 511. ProMab Biotechnologies
  • 512. Prometheus Laboratories
  • 513. Protagonist Therapeutics
  • 514. Protalix Biotherapeutics
  • 515. Proteimax
  • 516. ProvePharm Life Solutions
  • 517. Psagot Investment House
  • 518. PureTech Health
  • 519. PvP Biologics
  • 520. PVS Memorial Hospital
  • 521. PX'Therapeutics
  • 522. PYRAMID Laboratories
  • 523. QIC BioVentures
  • 524. Qilu Hospital of Shandong University
  • 525. QS Pharma
  • 526. Quaker BioVentures
  • 527. Queen's University
  • 528. RA Capital Management
  • 529. Radboud University
  • 530. Rambam Health Care Campus
  • 531. Rani Therapeutics
  • 532. Rebel Pharmaceuticals
  • 533. Reliance Life Sciences
  • 534. Rentschler Biopharma
  • 535. Rho Ventures
  • 536. Richter-Helm BioLogics
  • 537. Ridgeback Capital
  • 538. Riesner Verwaltungs
  • 539. Roche
  • 540. Rock Springs Capital
  • 541. Rosalind Capital
  • 542. Rosetta Capital
  • 543. RS Synthesis
  • 544. Ruijin Hospital
  • 545. SAFC
  • 546. Saffelberg Investments
  • 547. Sahlgrenska University Hospital
  • 548. Salix Pharmaceuticals
  • 549. Sandoz
  • 550. Sanofi
  • 551. Santhera Pharmaceuticals
  • 552. Sanyal Bio
  • 553. Schering-Plough
  • 554. Scientific Health Development Partners
  • 555. Scientific Protein Laboratories
  • 556. SciGen
  • 557. ScinoPharm
  • 558. Seachaid Pharmaceuticals
  • 559. Senn Chemicals
  • 560. Shanghai Zhongshan Hospital
  • 561. Sheatree Direct
  • 562. Sheba Hospital
  • 563. Shengnuo Peptide
  • 564. Shenzhen JYMed Technology
  • 565. Shionogi
  • 566. Shire
  • 567. Sichuang Provincial People's Hospital
  • 568. Sigma Capital Management
  • 569. Sigmoid Pharma
  • 570. Silicon Valley Bank
  • 571. Sinopep-Allsino Biopharmaceutical
  • 572. Slater Technology Fund
  • 573. Sofinnova Ventures
  • 574. Space Peptides
  • 575. Spaulding Clinical Research
  • 576. Sponsor
  • 577. Square 1 Bank
  • 578. SR One
  • 579. SRZ Properties
  • 580. St. Luke's Medical Center
  • 581. Stallergenes
  • 582. Starfish Ventures
  • 583. Stealth BioTherapeutics
  • 584. Stevanato Group
  • 585. Sublimity Therapeutics
  • 586. Sucampo Pharmaceuticals
  • 587. Summa Health Cancer Institute
  • 588. SV Health Investors
  • 589. Swiss Caps
  • 590. Swiss Investment group
  • 591. Symbiosis Pharmaceutical Services
  • 592. SynCo Bio Partners
  • 593. Synergy Pharmaceuticals
  • 594. Synermore Biologics
  • 595. Syngene International
  • 596. Syntex Pharm
  • 597. Synthetic Biologics
  • 598. Takanawa Pharma
  • 599. Takeda
  • 600. Takeda Ventures
  • 601. Tamares Capital
  • 602. Tamarix Technologies Group
  • 603. Tapemark
  • 604. Tarix Pharmaceuticals
  • 605. Tarsa Therapeutics
  • 606. TCG Lifesciences
  • 607. Tech Coast Angels
  • 608. Temasek
  • 609. Teva Pharmaceutical
  • 610. The Column Group
  • 611. The Halifax Group
  • 612. The Native Antigen Company
  • 613. Therapure Biopharma
  • 614. Thermo Fisher Scientific
  • 615. Thiel Foundation
  • 616. Third Rock Ventures
  • 617. Third Security
  • 618. Tiziana Life Sciences
  • 619. TNT Pharma
  • 620. TPG Biotech
  • 621. Transgene Biotek
  • 622. TranXenoGen
  • 623. Trenzyme
  • 624. TriHealth
  • 625. TVM Capital
  • 626. UCB Pharma
  • 627. Unigene Laboratories
  • 628. University Hospital of Leuven
  • 629. University Hospital of South Manchester
  • 630. University of Alabama
  • 631. University of Alberta
  • 632. University of British Columbia
  • 633. University of California
  • 634. University of Colorado
  • 635. University of Heidelberg
  • 636. University of Iowa
  • 637. University of Minnesota
  • 638. University of Montreal
  • 639. University of Nebraska
  • 640. University of Pennsylvania
  • 641. University of Rochester
  • 642. University of Southern California
  • 643. University of Texas
  • 644. University of Vienna
  • 645. University of Virginia
  • 646. University of Washington
  • 647. US Department of Defense
  • 648. US Department of Energy
  • 649. USV
  • 650. Vanderbilt-Ingram Cancer Center
  • 651. Varuma
  • 652. Venrock
  • 653. Ventria Bioscience
  • 654. VentureHealth
  • 655. Vertex Pharmaceuticals
  • 656. Vetter Pharma
  • 657. VHsquared
  • 658. Victory Park Capital
  • 659. Virginia Commonwealth University
  • 660. Virtus Inspire Ventures
  • 661. Vista Biologicals
  • 662. VIVUS
  • 663. vTv Therapeutics
  • 664. WACKER Biotech
  • 665. Waisman Biomanufacturing
  • 666. Wake Forest University Health Sciences
  • 667. Washington University School of Medicine
  • 668. Watson Laboratories
  • 669. Wellington Management Company
  • 670. West China Hospital
  • 671. West Penn Allegheny Health System
  • 672. WestRiver Management
  • 673. White Oak Global Advisors
  • 674. Wingate Institute of Neurogastroenterology
  • 675. WuXi AppTec
  • 676. WuXi Healthcare Ventures
  • 677. Wyeth Pharmaceuticals
  • 678. XBiotech
  • 679. Xiamen Weiyang Pharmaceutical
  • 680. Yale Center for Clinical Investigation
  • 681. Yissum
  • 682. Zealand Pharma
  • 683. Zhejiang Peptides Biotech
  • 684. Zhongshan Hospital
  • 685. Zhongshan University
  • 686. Ziff Asset Management
  • 687. Zosano Pharma